JP2018533912A5 - - Google Patents

Download PDF

Info

Publication number
JP2018533912A5
JP2018533912A5 JP2018513360A JP2018513360A JP2018533912A5 JP 2018533912 A5 JP2018533912 A5 JP 2018533912A5 JP 2018513360 A JP2018513360 A JP 2018513360A JP 2018513360 A JP2018513360 A JP 2018513360A JP 2018533912 A5 JP2018533912 A5 JP 2018533912A5
Authority
JP
Japan
Prior art keywords
alanine
amino acid
ckp
phenylalanine
acid selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018513360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533912A (ja
JP7166916B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/052012 external-priority patent/WO2017049009A1/en
Publication of JP2018533912A publication Critical patent/JP2018533912A/ja
Publication of JP2018533912A5 publication Critical patent/JP2018533912A5/ja
Priority to JP2022096301A priority Critical patent/JP7602514B2/ja
Application granted granted Critical
Publication of JP7166916B2 publication Critical patent/JP7166916B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018513360A 2015-09-15 2016-09-15 シスチンノットスキャフォールドプラットフォーム Active JP7166916B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022096301A JP7602514B2 (ja) 2015-09-15 2022-06-15 シスチンノットスキャフォールドプラットフォーム

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562219063P 2015-09-15 2015-09-15
US62/219,063 2015-09-15
PCT/US2016/052012 WO2017049009A1 (en) 2015-09-15 2016-09-15 Cystine knot scaffold platform

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022096301A Division JP7602514B2 (ja) 2015-09-15 2022-06-15 シスチンノットスキャフォールドプラットフォーム

Publications (3)

Publication Number Publication Date
JP2018533912A JP2018533912A (ja) 2018-11-22
JP2018533912A5 true JP2018533912A5 (https=) 2019-10-31
JP7166916B2 JP7166916B2 (ja) 2022-11-08

Family

ID=57068206

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018513360A Active JP7166916B2 (ja) 2015-09-15 2016-09-15 シスチンノットスキャフォールドプラットフォーム
JP2022096301A Active JP7602514B2 (ja) 2015-09-15 2022-06-15 シスチンノットスキャフォールドプラットフォーム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022096301A Active JP7602514B2 (ja) 2015-09-15 2022-06-15 シスチンノットスキャフォールドプラットフォーム

Country Status (22)

Country Link
US (8) US10428125B2 (https=)
EP (1) EP3350215B1 (https=)
JP (2) JP7166916B2 (https=)
KR (1) KR102846388B1 (https=)
CN (4) CN120248097A (https=)
AR (1) AR106032A1 (https=)
AU (2) AU2016323445B2 (https=)
BR (1) BR112018002263A2 (https=)
CA (1) CA2996006A1 (https=)
CL (2) CL2018000668A1 (https=)
CO (1) CO2018002510A2 (https=)
CR (1) CR20180169A (https=)
IL (2) IL294568A (https=)
MA (1) MA42828A (https=)
MX (1) MX2018002922A (https=)
MY (1) MY190552A (https=)
PE (1) PE20181293A1 (https=)
PH (1) PH12018500577A1 (https=)
RU (1) RU2770384C2 (https=)
TW (1) TWI799366B (https=)
UA (1) UA125505C2 (https=)
WO (1) WO2017049009A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer
IL298878A (en) 2020-06-11 2023-02-01 Genentech Inc Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same
WO2025193946A2 (en) * 2024-03-14 2025-09-18 Genentech, Inc. Peptides binding lrrc15 and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US918814A (en) 1907-10-30 1909-04-20 Handy Mfg Company Funnel.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
CZ20003099A3 (cs) 1998-02-25 2002-04-17 Lexigen Pharmaceuticals Corporation Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
JP2003528632A (ja) 2000-03-31 2003-09-30 インスティティ・パスツール 血管内皮成長因子(vegf)−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
MXPA02011808A (es) 2000-06-01 2003-04-10 Amgen Inc Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos.
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP1404297B1 (en) 2001-06-12 2011-04-27 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
US7052705B2 (en) 2001-10-03 2006-05-30 Regeneron Pharmaceuticals, Inc. Anti-angiogenic peptides
GB0130738D0 (en) 2001-12-21 2002-02-06 Serono Internat S A Protein
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
DK1844337T3 (da) 2005-01-24 2013-09-30 Pepscan Systems Bv Bindingsforbindelser, immunogene forbindelser og peptidmimetika
US20060204548A1 (en) 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US20090305994A1 (en) 2005-06-29 2009-12-10 D Andrea Lucas Domenico Compounds Modulating Vegf Receptor and Uses Thereof
EP1929073A4 (en) * 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
CN101583370A (zh) * 2005-09-27 2009-11-18 阿穆尼克斯公司 蛋白质药物及其用途
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
US7918814B2 (en) 2006-05-02 2011-04-05 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
CA2670990A1 (en) 2006-12-01 2008-06-12 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
CA3076115C (en) 2007-08-21 2022-06-28 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
US8394924B2 (en) * 2008-10-23 2013-03-12 Massachusetts Institute Of Technology Directed engagement of activating Fc receptors
EP3785735A1 (en) * 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
US8778888B2 (en) * 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
US20110207653A1 (en) 2009-12-21 2011-08-25 Adrian Raiche Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent
WO2011079232A1 (en) 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
US8339139B2 (en) * 2010-01-29 2012-12-25 Infineon Technologies Ag System and method for testing a circuit
EP2638173B1 (en) * 2010-11-08 2019-06-19 The Board of Trustees of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
UA112769C2 (uk) * 2011-02-18 2016-10-25 Ендо Фармасьютікалз Інк. Аміноінданові сполуки і їх застосування при лікуванні болю
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
EP2890389A1 (en) * 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
GB201218278D0 (en) * 2012-10-11 2012-11-28 Cyclogenix Ltd Translocating peptide
WO2014063012A1 (en) * 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺

Similar Documents

Publication Publication Date Title
JP2013518115A5 (https=)
CA2122340C (en) Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JP2016512255A5 (https=)
JP7705160B2 (ja) 生物活性複合体の調製
JP2018533912A5 (https=)
JP2017534676A5 (https=)
RU2015143472A (ru) Конъюгаты инсулин-инкретин
TW201028162A (en) Amide based glucagon superfamily peptide prodrugs
RS20050530A (sr) Vezivna sredstva koja inhibiraju miostatin
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
EP2428215A1 (en) An angiogenesis inducing agent comprising recombinant gelatin
MX2011001028A (es) Analogos truncados de polipeptidos de insulinotropicos dependientes de glucosa.
TW201204392A (en) Dipeptide linked medicinal agents
MX2011008774A (es) Conjugados citotoxicos que tienen un compuesto de unión de receptores de neuropeptidos y.
WO2010147109A1 (ja) 遺伝子組み換えゼラチン及び塩基性線維芽細胞増殖因子を含む血管新生誘導剤
JP6598344B2 (ja) 環状ペプチドをタンパク質構造に提示させる超汎用法
CONLON et al. Primary structure and conformational analysis of peptide methionine—tyrosine, a peptide related to neuropeptide Y and peptide YY isolated from lamprey intestine
FR2677362A1 (fr) Neuropeptides de la famille des tachykinines.
RU2018113442A (ru) Платформа на основе каркаса цистинового узла
JP6548126B2 (ja) Iii型コラーゲン産生促進剤
JP3368282B2 (ja) 安定なポリペプチド組成物
KR20140026372A (ko) 혈액-뇌 장벽을 투과하는 약물 전달체, 펩티드 및 이의 용도
JP6656661B2 (ja) プレキシンの結合調節剤
CN119285744A (zh) 逆向-反转肽
CN110678550A (zh) 长效肾上腺髓质素衍生物